Saturday, 12 July 2025
  
Login

Australia's most trusted
source of pharma news

Saturday, 12 July 2025
News

Company snags two big names

 Posted 28 October 2024 AM

Cell and gene therapy company RhemaGen Australia which is engineering a new class of therapeutics for major autoimmune diseases, has nabbed two high-profile names in Australian industry with ex-Janssen Managing Director Bruce Goodwin and ex-ARCS CEO Shanny Dyer joining the board.

RheumaGen's lead program, RG0401, is designed as a one-time curative treatment for rheumatoid arthritis (RA). The Australian arm of the business will be responsible for advancing the HLA gene-edited cell therapy for refractory RA to a Phase I clinical trial in Australia and for commercialising HLA gene-edited cell therapies for rheumatoid arthritis locally.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (11)

Clinical & Medical, R&D (9)

Regulatory, Pharmacovigilance & QA (3)

Devices (1)

Other (17)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.